Objective: To determine the clinical and laboratory response rate of a gemcitabine and docetaxel combination in human adenocarcinoma of the pancreas in vitro and in vivo. Methods: Fifteen patients with unresectable pancreatic cancer were treated with gemcitabine, 900 mg/m2, and docetaxel, 90 mg/m2, every 3 weeks. Two human pancreatic cancer lines were tested in MTT assays for their response to titrations of gemcitabine and/or docetaxel at different time points and scheduling for biochemical synergy or additional antitumor effects. Results: In vitro testing showed that these two agents were minimally effective alone but when combined, they displayed additional biochemical antiproliferative effects in MTT assays. With intent-to-treat analysis of all 15 patients, 4 patients (27%) achieved an objective response by CT scan, including one complete response. Seven patients (47%) had subjective improvement and decreased serum marker levels of CA 19-9. None of the 12 patients without prior therapy developed nadir white blood cell counts below 1,000/mm3; 2 of 3 patients with prior radiation therapy developed nadir white blood cell counts below 1,000/mm3. Conclusion: This regimen is well tolerated and appears to have a significant objective response rate. Gemcitabine and docetaxel antitumor effects are additive in vitro, which may help to explain the response rate.

Keywords:
Gemcitabine, Docetaxel, Pancreas, Adenocacinoma, Cancer
1.
Schnall SF, Macdonald JS: Chemotherapy of adenocarcinoma of the pancreas. Semin Oncol 1996;23:220–228.
2.
Moertel CG: Chemotherapy of gastrointestinal cancer. Clin Gastroenterol 1976;5:777–793.
3.
Casper ES, Green MR, Kelsen DP, Heelan RT, Brown TD, Flombaum CD, Trochanowski B, Tarassoff PG: Phase II trial of gemcitabine (2,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 1994;12:29–34.
4.
Rothenberg ML, Moore MJ, Cripps MC, Andersen JS, Portenoy RK, Burris HA 3rd, Green MR, Tarassoff PG, Brown TD, Casper ES, Storniolo AM, Von Hoff DD: A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol 1996;7:347–353.
5.
Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 1997;15:2403–2413.
6.
Sakata Y, Takemori H, Suzuki H: Chemotherapy for pancreatic cancer (in Japanese). Gan To Kagaku Ryoho 1996;12:1647–1650.
7.
Fumoleau P, Perrocheau G, Maugard-Louboutin C, Lemevel B: Paclitaxel (Taxol) and docetaxel (Taxotere): Results of phase II trials in monochemotherapy (in French). Bull Cancer 1995;82:629–636.
8.
Kaye SB: Docetaxel (Taxotere) in the treatment of solid tumors other than breast and lung cancer. Semin Oncol 1995;22:(2 suppl 4):30–33.
9.
Androulakis N, Kourousis C, Dimopoulos MA, Samelis G, Kakolyris S, Tsavaris N, Genatas K, Aravantinos G, Papadimitriou C, Karabekios S, Stathopoulos GP, Georgoulia V: Treatment of pancreatic cancer with docetaxel and granulocyte colony-stimulating factor: A multicenter phase II study. J Clin Oncol 1999;17:1779–1785.
10.
Georgoulias V, Kourousis C, Androulakis N, Kakolyris S, Dimopoulos MA, Bouros D, Papadimitriou C, Hatzakis K, Heras P, Kalbakis K, Kotsakis T, Vardakis N, Meramveliotakis N, Hatzidaki D: Docetaxel (Taxotere) and gemcitabine in the treatment of non-small cell lung cancer: Preliminary results. Semin Oncol 1997;24(4 suppl 14):S14-22–S14-25.
11.
Spiridonidis CH, Laufman LR, Jones J, Rhodes VA, Wallace K, Nicol S: Phase I study of docetaxel dose escalation in combination with fixed weekly gemcitabine in patients with advanced malignancies. J Clin Oncol 1998;16:3866–3873.
12.
Cascinu S, Gasparini G, Catalano V, Silva RR, Pancera G, Morabito A, Giordani P, Gattuso D, Catalano G: A phase I–II study of gemcitabine and docetaxel in advanced pancreatic cancer: A report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). Ann Oncol 1999;10:1377–1379.
13.
Van Rompay AR, Johansson M, Karlsson A: Phosphorylation of deoxycytidine analog monophosphates by UMP-CMP kinase: Molecular characterization of the human enzyme. Mol Pharmacol 1999;56:562–569.
14.
Sawada N, Ishikawa T, Fukase Y, Nishida M, Yoshikubo T, Ishitsuka H: Induction of thymidine phosphorylation activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res 1998;4:1013–1019.
15.
McKenzie R, Fried MW, Sallie R, Conjeevaram H, Di Bisceglie AM, Park Y, Savarese B, Kleiner D, Tsokos M, Luciano C, et al: Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N Engl J Med 1995;333:1099–1105.
16.
Nangaku M, Sato-Yoshitake R, Okada Y, Noda Y, Takemura R, Yamazaki H, Hirokawa N: KIF1B, a novel microtubule plus end-directed monomeric motor protein for transport of proteins to mitochondria. Cell 1994;79:1209–1220.
© 2001 S. Karger AG, Basel
2001
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.